Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Menen – page 120

1 845 clinical trials in Menen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Menen at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Menen

Open in trial search

Tourette's disorder

Not recruiting

Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Gemlapodect
  • Sponsor:Noema Pharma AG

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study of JNJ-68284528 for Treating Multiple Myeloma in Patients Using Ciltacabtagene Autoleucel and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study Comparing Loncastuximab Tesirine and Rituximab with Standard Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:ADC Therapeutics SA

Study on Nivolumab and Ipilimumab for Patients with Untreated Unresectable or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effectiveness and Safety of CYP-001 and Corticosteroids for Adults with High-Risk Acute Graft Versus Host Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Mesenchymoangioblast-Derived Mesenchymal Stem Cells
  • Sponsor:Cynata Therapeutics Limited

Cardiac failure+1

Not recruiting

Study on Vericiguat for Children with Heart Failure from Left Ventricular Systolic Dysfunction

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Everolimus
  • Sponsor:Rayzebio Inc.

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Gastrooesophageal cancer+5

Not recruiting

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Menen

What the registry says about research in the country

01 Advanced Lung Cancer Research

Investigating innovative treatments for Non-Small Cell Lung Cancer (NSCLC), with a focus on patients carrying specific genetic mutations like EGFR Exon 20 insertions. The research evaluates combination therapies using zipalertinib with traditional chemotherapy to improve treatment outcomes.

  • Targeted Therapy Development
  • Genetic Mutation Analysis
  • Combination Treatment Strategies

Studies aim to determine optimal dosing and measure progression-free survival rates in advanced cases.

02 Immunotherapy Research

Evaluating the effectiveness of therapeutic cancer vaccines compared to conventional chemotherapy in treating metastatic NSCLC patients. The research specifically focuses on patients with HLA-A2 positive phenotype who have experienced immunotherapy failure.

  • Cancer Vaccine Development
  • Treatment Resistance Studies
  • Overall Survival Analysis

Research aims to demonstrate improved survival outcomes using novel vaccine-based approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.